Inve India ▾

Vimta Labs share price & results

Vimta Labs· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

India's #1 CRO in pharma analytical & food testing, plus preclinical, environment & electronics testing labs.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue109 ₹ crore+11.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin34.0 %−1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit21.0 ₹ crore+10.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equityUnavailable−5.1 ptsFY Mar 2024 vs FY Mar 2023Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow marginUnavailable−16.4 ptsFY Mar 2024 vs FY Mar 2023Fiscal yearFY · period unavailableNot in the analysed materials. No older figure is substituted.
Revenue growth (YoY)Unavailable−14.4 ptsFY Mar 2024 vs FY Mar 2023Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 5 judged targets kept · 7 open · verdicts reflect calls analysed to Q1 FY27.

Vimta Labs management guidance track record on Inve: 12 targets tracked across analysed earnings calls (2 achieved, 3 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
Biologics CommercializationCommercialization of biologics services projected for Q1 FY27
Call transcript, Q1 FY26 · 21 Jul 2025		Q1 FY26Q1 FY27:Successfully secured the first order for Biologics services and operationalized the facility in Q1 FY27, meeting the projected timeline. Management confirmed: 'The commercialization has begun already in Q1. The client is onboarded in Q1.'
Call transcript, Q1 FY27 · 20 Jul 2026		Achieved
FY26 Annual RevenueAchieve an INR 500 crores (5,000M) annual revenue run rate for FY26
Call transcript, Q2 FY26 · 3 Nov 2025		Q2 FY26Q1 FY27:This promise for FY26 was concluded as 'missed' in the previous quarter and was not mentioned.
Call transcript, Q1 FY27 · 20 Jul 2026		Missed
Facility CapacityNew facility space will be sufficient for the next 5 years of growth
Call transcript, Q1 FY26 · 21 Jul 2025		Q1 FY26Q1 FY27:Management confirmed the existing infrastructure is sufficient for the next 4-5 years of growth, reiterating the long-term capacity plan.
Call transcript, Q1 FY27 · 20 Jul 2026		On Track

Source: Inve Guidance Tracker for Vimta Labs · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Vimta Labs's 12 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 9 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹489.25 +4.54% · +₹21.25

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −27.2% 1Y

₹400₹500₹600₹700Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 3 Nov 2025Q3 FY26 — 28 Jan 2026Q4 FY26 — 6 May 2026Q1 FY27 — 20 Jul 2026

1Y: ₹672 on 24 Oct 2025 → ₹489.25. High ₹725.4 (31 Oct 2025), low ₹380.7 (30 Mar 2026).

Previous close
₹468
Market cap
₹2.2k Cr
52-week range
₹380.7 – ₹725.4
One year
−26.81%

Overview

Symbol
NSE:VIMTALABS
Exchange
NSE
Currency
INR

What Vimta Labs does

Based on the company's own presentations, annual report and earnings calls.

Vimta Labs is a contract research and testing organisation (CRTO), founded in 1984, that runs accredited laboratories for pharmaceutical, biopharma, agrochemical, food, electronics and environmental clients. It earns fee-for-service revenue across four business lines: drug discovery and development services (pharma analytical, clinical research, preclinical/toxicology studies), food and agri testing, electricals and electronics testing and certification, and environment testing and consultancy. Its labs hold approvals from Indian and global regulators (USFDA, WHO, EMA, MHRA, FSSAI, BIS, OECD-GLP, NABCB among others), letting it serve both domestic manufacturers and overseas pharma/food clients out of its Hyderabad-headquartered network.

Segments

  • Drug discovery and development services
  • Food & Agri Testing
  • Electricals & Electronics Testing & Certification
  • Environment Testing & Consultancy
Multi-disciplinary workforce
1,384 employees, 71.11% scientists
Labs and offices across India
10
Lab infrastructure
600,000+ sq. ft. of ultra-modern lab space
Experience in the CRTO industry
41+ years (established 1984)
Regulatory audits cleared
~100 successful regulatory audits
Market position
#1 in India in Pharma Analytical Testing and in Food Testing; among top 5 in India in Preclinical Research and in Environment Testing; a leading electronics & electricals testing lab in South India
Founded 1984Headquarters Hyderabad, IndiaEmployees 1,384 (FY26 (year ended March 2) Company website

How the price took the results

close before → close after

Q1 FY27
−5.2%
20 Jul
Q4 FY26
+3.2%
6 May
Q3 FY26
−10.3%
28 Jan
Q2 FY26
−5.9%
3 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Vimta Labs

Free account: one company. Everything above stays public.

Write why you follow Vimta Labs and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Vimta Labs

Guides on how to read this kind of business and the numbers that matter.